All In Biotech

Drug Trial Radar · NCT06344052

To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma

A Phase 2 Study to Assess the Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Sep 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Apr 9, 2024

Primary completion

Sep 30, 2026

Study completion Mar 30, 2029

Sponsor

Lead sponsor
Stamford Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Apr 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the efficacy of using SP-002 in participants with locally advanced Basal cell carcinoma. The main question it aims to answer is what the objective response rate for a basal cell carcinoma tumor is following 1 or 3 cycles of SP-002 treatment given as an add-on to hedgehog pathway inhibitor therapy. Researchers will compare the objective response rate for treated Basal cell carcinoma tumors between 3 treatment Arms. * Arm 1 participants will receive daily hedgehog pathway inhibitor, and 3 cycles of SP-002 treatment. * Arm 2 participants will receive daily hedgehog pathway inhibitor, and 1 cycle of SP-002 treatment. * Arm 3 participants will receive daily hedgehog pathway inhibitor only.

Conditions

  • Basal Cell Carcinoma

Interventions

  • SP-002Drug

    SP-002 is a replication deficient adenovirus-5 encoding human interferon gamma (IFNγ), designed for intra-tumoral administration

  • VismodegibDrug

    The HHPI vismodegib is currently indicated for the treatment of adult patients with metastatic BCC, or with laBCC where surgery and/or radiation therapy are not appropriate.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rateTime frame: Week 26

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Phoenix, Arizona · Recruiting

  • Research Site

    Boca Raton, Florida · Recruiting

  • Research Site

    Coral Springs, Florida · Recruiting

  • Research Site

    Cutler Bay, Florida · Recruiting

  • Research Site

    Rockville, Maryland · Recruiting

  • Research Site

    Lee's Summit, Missouri · Recruiting

  • Research Site

    Rochester, New York · Recruiting

  • Research Site

    Cedar Park, Texas · Recruiting

  • Research Site

    Humble, Texas · Recruiting

  • Research Site

    Longview, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.